SKYE Stock Price | Skye Bioscience, Inc. Common Stock P/E, Revenue, EPS, & Forecasts

Skye Bioscience, Inc. Common Stock • SKYE

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Skye Bioscience, Inc. Common Stock

Ticker

SKYE

Trading on

NASDAQ

ISIN

US83086J2006

Industry

Biotechnology

Sector

Healthcare

CEO

Punit S. Dhillon B.A.

Headquarters

11250 El Camino Real, San Diego, CA, United States, 92130

Employees

Website

https://skyebioscience.com

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Metrics

BasicAdvanced

Market cap

$116M

P/E ratio

EPS

-$0.83

Dividend Yield

0.00%

Beta

1.67

Forward P/E ratio

EBIDTA

$-35.4M

Ex dividend date

Price & volume

Market cap

$116M

Average daily volume

1.9M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

1.96

Earnings

EPS

-$0.83

EPS estimate (current quarter)

-$0.29

EPS estimate (next quarter)

-$0.28

EBITDA

$-35.4M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.67

52-week High

$7.47

52-week Low

$1.14

50-day moving average

$2.28

200-day moving average

$3.12

Short ratio

12.09

Short %

13.66%

Management effectiveness

ROE (TTM)

-47.27%

ROA (TTM)

-28.04%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

31M

Float

16.1M

Insiders %

1.44%

Institutions %

80.79%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 7 analysts.

Average price target

$15.50

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.20

-$0.19

-5.26%

Q2 • 24Missed

-$0.10

-$0.25

60.00%

Q3 • 24Beat

-$0.29

-2.18%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-9.7M

-∞%

Q4 • 24

$0M

$-11.1M

-∞%

Q1 • 25

NaN%

13.92%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$72.8M

$4.6M

6.34%

Q4 • 24

$64.8B

$5.54B

8.55%

Q1 • 25

88,946.01%

120,083.59%

34.97%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-8.2M

$0.1M

$0M

$-8.2M

Q4 • 24

$-9.19B

$-12.8M

$0M

$-9.19B

Q1 • 25

112,286.69%

-14,267.64%

-100.00%

111,679.76%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Skye Bioscience, Inc. Common Stock share?

Skye Bioscience, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Skye Bioscience, Inc. Common Stock have?

Skye Bioscience, Inc. Common Stock currently has 31M shares.

Does Skye Bioscience, Inc. Common Stock pay dividends?

No, Skye Bioscience, Inc. Common Stock doesn't pay dividends.

What is Skye Bioscience, Inc. Common Stock 52 week high?

Skye Bioscience, Inc. Common Stock 52 week high is $7.47.

What is Skye Bioscience, Inc. Common Stock 52 week low?

Skye Bioscience, Inc. Common Stock 52 week low is $1.14.

What is the 200-day moving average of Skye Bioscience, Inc. Common Stock?

Skye Bioscience, Inc. Common Stock 200-day moving average is $3.12.

Who is Skye Bioscience, Inc. Common Stock CEO?

The CEO of Skye Bioscience, Inc. Common Stock is Punit S. Dhillon B.A..

How many employees Skye Bioscience, Inc. Common Stock has?

Skye Bioscience, Inc. Common Stock has 16 employees.

What is the market cap of Skye Bioscience, Inc. Common Stock?

The market cap of Skye Bioscience, Inc. Common Stock is $116M.

What is the P/E of Skye Bioscience, Inc. Common Stock?

The current P/E of Skye Bioscience, Inc. Common Stock is null.

What is the EPS of Skye Bioscience, Inc. Common Stock?

The EPS of Skye Bioscience, Inc. Common Stock is -$0.83.

What is the PEG Ratio of Skye Bioscience, Inc. Common Stock?

The PEG Ratio of Skye Bioscience, Inc. Common Stock is null.

What do analysts say about Skye Bioscience, Inc. Common Stock?

According to the analysts Skye Bioscience, Inc. Common Stock is considered a buy.